SOPHiA GENETICS announced that BioReference® Health, LLC, will implement SOPHiA GENETICS' technology and add MSK-ACCESS® liquid biopsy to its test suite. With the implementation of SOPHiA GENETICS, BioReference will be the first laboratory globally to adopt MSK-ACCESS® powered with SOPHiA DDM?. The offering will be commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Oncology in 2024.

Since January 2023, Memorial Sloan Kettering Cancer Center (MSK) and SOPHiA GENETICS have been working on merging MSK-ACCESS® technology with the SOPHiA DDM? Platform algorithms to provide a comprehensive liquid biopsy assay available on the decentralized platform. The new offering takes advantage of the sophisticated analytics of the SOPHiA DDM?

Platform, combining its state-of-the-art algorithms and global network with the scientific and clinical expertise of MSK in cancer genomics. The onboarding of BioReference aims to bring access to world-class liquid biopsy testing to the laboratory's customers across the country. BioReference currently operates 10 laboratory facilities across the U.S. and provides scientific expertise in oncology, urology, and women's health.

The laboratory's oncology division, GenPath Oncology, offers a comprehensive portfolio to support the continuum of care of cancer patients ? from risk assessment to treatment planning. Deploying in-house liquid biopsy testing will enable the laboratory to analyze samples from a simple, non-invasive blood draw, allowing for less invasive monitoring of cancers.

The offering will incorporate SOPHiA GENETICS' advanced genomic analysis, made possible with artificial intelligence (AI), and expedited streamlined insights to increase the ability of clinician researchers to practice precision medicine. MSK-ACCESS® powered with SOPHiA DDM? is being designed to align with the most up-to-date guidelines and clinical trial data, reflecting major biologically actionable biomarkers.

In addition to quickly providing analysis and insights, the SOPHiA DDM? Platform will allow BioReference to retain ownership of its database and obtain reproducible data that can help accelerate future work.